- Open Access
Cost-minimization analysis in a blind randomized trial on small-incision versus laparoscopic cholecystectomy from a societal perspective: sick leave outweighs efforts in hospital savings
Trials volume 10, Article number: 80 (2009)
After its introduction, laparoscopic cholecystectomy rapidly expanded around the world and was accepted the procedure of choice by consensus. However, analysis of evidence shows no difference regarding primary outcome measures between laparoscopic and small-incision cholecystectomy. In absence of clear clinical benefit it may be interesting to focus on the resource use associated with the available techniques, a secondary outcome measure. This study focuses on a difference in costs between laparoscopic and small-incision cholecystectomy from a societal perspective with emphasis on internal validity and generalisability
A blinded randomized single-centre trial was conducted in a general teaching hospital in The Netherlands. Patients with reasonable to good health diagnosed with symptomatic cholecystolithiasis scheduled for cholecystectomy were included. Patients were randomized between laparoscopic and small-incision cholecystectomy. Total costs were analyzed from a societal perspective.
Operative costs were higher in the laparoscopic group using reusable laparoscopic instruments (difference 203 euro; 95% confidence interval 147 to 259 euro). There were no significant differences in the other direct cost categories (outpatient clinic and admittance related costs), indirect costs, and total costs. More than 60% of costs in employed patients were caused by sick leave.
Based on differences in costs, small-incision cholecystectomy seems to be the preferred operative technique over the laparoscopic technique both from a hospital and societal cost perspective. Sick leave associated with convalescence after cholecystectomy in employed patients results in considerable costs to society.
ISRCTN Register, number ISRCTN67485658.
Langenbuch's classical cholecystectomy has been the gold standard for over a century . Since the mid 1970's surgeons began shortening their incisions because of a presumed quicker convalescence [2, 3]. Soon thereafter, laparoscopic cholecystectomy (LC) was introduced, and rapidly expanded around the world . The popularity of this procedure was partly based on an appealing technological innovation as well as industry driven motives and not primarily a result of an evidence-based approach .
Analysis of evidence in Cochrane reviews shows no difference regarding primary outcome measures (mortality and complications) between the three operative techniques of cholecystectomy (open, small-incision and laparoscopic) [6–8]. In absence of clear clinical benefit based on these meta-analyses it may be interesting to focus on the resource use associated with the available techniques. We performed a single blind randomized clinical trial focusing on a secondary outcome: costs. In a previous paper we emphasized intrinsic validity of this trial, proved reproducibility of results from other trials and showed generalisability in a general teaching hospital.
The costs of LC and small-incision cholecystectomy (SIC) have been compared in six randomized trials. [10–15] These available studies are inconsistent in outcome and conclusions, use different perspectives and most of the trials suffer methodological shortcomings.
The research question is whether there is a difference in costs from a societal perspective between small-incision and laparoscopic cholecystectomy using a blind randomized approach. In a detailed cost analysis attention has to be paid to both direct and indirect costs as well as the perspective of the analysis. Furthermore, cost prices, budget prices and tariffs have to be distinguished.
In meta-analyses we found no major differences in clinical outcome measures (mortality, complications, conversions, hospital stay, and convalescence) between LC and SIC for patients with symptomatic cholecystolithiasis. We also found no differences considering pulmonary function, health status, and cosmesis. [16, 17] Costs are a secondary outcome measure and ultimately may be a decisional factor. This paper focuses on cost-minimization analysis.
Medical Ethics Committee approval for this single-centre trial was obtained in September 2000. Between January 2001 and January 2004, all patients referred to our surgical outpatient's clinic with symptomatic cholecystolithiasis (confirmed by ultrasonography) were considered for inclusion in this study.
Inclusion- and exclusion criteria
Inclusion criteria were male or female patients with symptomatic cholecystolithiasis, aged 18 years or older at recruitment, reasonable to good health (ASA I or II), no known relevant allergies, and a signed informed consent letter.
Exclusion criteria were age younger than 18 years, choledocholithiasis (icterus, acholic faeces and/or bilirubine of twice normal range), cholangitis, known pregnancy, moderate to severe systemic disease (ASA III and higher), known cirrhosis of the liver, history of abdominal malignancy, previous upper abdominal surgery (precluding a laparoscopic approach), psychiatric disease, or a reasons (e.g. lack of knowledge of the Dutch language) that might make follow-up or completion of questionnaires unreliable.
Obesity was not an exclusion criterion. Recovery after successful endoscopic treatment of choledocholithiasis was not a contra-indication. Acute cholecystitis was excluded.
A random number table was used for generation of the allocation sequence  and the allocation concealment was guaranteed by using sealed envelopes. Patients were randomized after induction of anesthesia. An employee of the secretary office opened an envelope. Details were recorded in a case record form. Otherwise the procedure was recorded as 'trial cholecystectomy'.
All patients had a standard anesthesia regime. Premedication, medications for induction and continuation of anesthesia, as well as respiration during surgery were standardized. Residents (from 2nd year on) performed most of the operations. In case of technical difficulties either trial technique could be converted to open cholecystectomy (OC). Wounds were covered with standard wound dressings. In this way blinding of patients, nurses, and ward physicians was achieved. Postoperative analgesics and medication for nausea were standardized.
Open introduction was performed in all laparoscopic cholecystectomies. Pneumoperitoneum was created with an intra-abdominal pressure up to 12 mmHg. Three trocars for instruments were inserted. The dissection of the cystic artery and cystic duct, identifying Calot's triangle, was performed using a three points 'flag' technique  The cystic duct and artery were clipped and transected. All instruments were reusable.
In concordance with literature a cut-off point of 8 cm was used to differentiate between SIC and OC.[14, 19, 21–26] The incision was placed over the musculus rectus abdominis. No special equipment was used. Access to the peritoneum was obtained by a 'muscle splitting' technique. The gallbladder was dissected by a 'fundus-first' technique. The cystic duct and artery were ligated and the gallbladder was removed. Posterior and anterior fascias were closed separately. If the length of the incision exceeded 8 cm, the operation was considered to be a conversion to OC.
Early oral intake and mobilization were encouraged. Patients left the hospital as soon as they were able to do so. Incidental 'social' reasons for lengthening of hospital stay (by a few days) were accepted. Hospital stay was defined as the number of postoperative nights in hospital. For logistic reasons, we were not able to blind the surgeon during follow-up. Follow-up was standardized after 2 weeks, 6 weeks and 3 months. Patients were encouraged to resume work as soon as possible.
Analysis and sample size
In meta-analyses no differences in patient-relevant outcomes appear to be present between these two techniques. Assuming no differences in primary outcome measures, sample size calculation was based on anticipated differences of costs. The direct costs of the first 50 patients in the trial were calculated so as to estimate the likely range of differences in costs and their standard deviations. On this basis, we estimated that 120 patients per group would be needed to detect a difference of 10% in direct costs using an α of 0.05 and a β of 0.9.
Analyzing differences in costs due to complications between both techniques would require another sample size including thousands of patients in order to possibly find significant results. Consequently, differences in complication costs were therefore not statistically tested in our study. However, these costs were reported to illustrate their impact on total costs.
All data were stored in a case record form (Access®) based on a patient-linked trial registration number. A double data entry was performed. Comparisons were made on an intention to treat basis. Calculations were made using SPSS 11.0®.
The chi-square test was used for dichotomous outcome. Normality of data was checked using the Kolmogorov-Smirnov test.  Levene's test was used for checking equality of variances. When the condition of normality and equal variances was met, the t-test for independent data was used; otherwise the nonparametric Mann-Whitney U test for independent data was used.
Methods of cost analysis
As cost items that are equally present in both groups do not contribute to differences, it can be argued that these can be left out of consideration. On the other hand all costs contribute to the total amount and the incremental value. Therefore, we strived for reporting costs in detail.  For each cost item, hospital costs, overhead costs and consultants' costs were included if appropriate (Table 1).
All costs were calculated in euros (2004). All direct medical costs were summarized in different categories including costs due to complications (admittance, operative, outpatients' clinic, and complications).
As there are no relevant or significant differences in clinical outcome [8, 16] or quality-of-life , a cost-minimization analysis seems most appropriate. Afterwards, differences in costs can be balanced with other (thus far unknown) differences in outcome.
In evaluating costs, it is important to be complete in accounting for all items. Therefore, in general a societal perspective is recommended. [30–32] In a societal perspective all costs are included in the analysis (patient, hospital and losses in production), irrespective of the stakeholder incurring the costs or who benefits from treatment. Moreover, today's limited health care budgets warrant proper economic evaluation of treatments, especially when incidences and impact on economy are high (like in symptomatic cholecystolithiasis).
Definitions of cost categories
Direct medical costs
costs resulting from outpatient clinic, hospital admittance, surgery, complications, etcetera.
Direct non-medical costs
costs arising from outside health care immediately related to treatment (e.g. traveling costs from patients). The problem is that it is very difficult to estimate these costs accurately in all patients. We assume that these costs are equal for both groups. Moreover, since the vast majority of patients have an uncomplicated recovery, these costs are assumed not to contribute importantly to total costs.
Indirect non-medical costs
costs due to loss of productivity related to employment status of patients. These costs arise from loss of productivity caused by sick leave, disabled for work or mortality. We decided to use the friction cost method. [31–36]
Tariffs, cost prices, budget prices and overhead costs
In cost assessments tariffs, cost prices and budget prices have to be distinguished. Tariffs are costs that are calculated for insurance companies. Tariffs are nearly always different from real costs. Budget prices on the other hand are figures used for internal (hospital) calculations, and do not reflect real costs either. Cost prices are real costs for procedures and are usually not used in hospital administrations. These cost prices can be calculated but are sometimes difficult to retrieve.
Apart from these differences there are costs for depreciation and interest. Different methods are used and no uniform guidelines exist how to estimate these overhead costs, neither do arguments exist that one method is superior over the other. In our hospital a percentage incremental value is added to every cost price. We applied this method in our study.
Description of procedures and measurement of resources
In this cost-minimization analysis, all resources were prospectively recorded. A visit to the general practitioner, diagnostic examinations, and costs due to preoperative outpatient clinic visits were counted. Hospital stay was counted as the number of overnights stay. Medication use is included in admittance cost prices. Operative costs and the costs of anesthesiologists were calculated according to operating room occupancy. Standard materials and equipment used in the operating room including costs associated with cleaning and sterilisation are included in hospital costs for surgery. The costs of the surgeon and resident were calculated from the time of incision to last suture. In laparoscopic instruments extra laparoscopy-specific materials like clips and endobags were calculated, but monitor, gass-insufflator, and camera were not calculated as these were considered present. In the small-incision procedure no extra equipment other than standard instruments is needed. In follow-up the time of the surgeon was calculated. Finally, if complications occurred, all extra costs were included. Costs of consultants were calculated using the national agreed honorarium (140 euro per hour) (Table 1).
Several sensitivity analyses were performed to yield an impression of the effect of changes on total costs. Variables were considered if the costs were appreciable and a change in the costs of the variable could be possible and clinically relevant:
The influence of the use of disposable instead of reusable laparoscopic instruments on total costs.
Influence of reduction of time back-to-work by one week on total costs.
Influence of the reduction of hospital stay by one night on total costs.
All trial patients were included and operated between January 2001 and March 2004. Leaving unwilling and excluded patients out of consideration, 366 patients visiting the outpatient clinic of the hospital for symptomatic cholecystolithiasis fulfilled the inclusion criteria and were initially included in the trial. A total of 102 patients were not randomized for a variety of reasons (Figure 1).  After randomizing 264 patients, another 7 patients were excluded for the following reasons: unwilling to continue in the trial (n = 2), intra-operative suspicion of malignancy (n = 2), transfer to a non-surgical ward (n = 1), inadvertent participation in multiple trials (n = 1), and inadequate Dutch language skills (n = 1). A total of 257 patients were left for analysis (LC:120 and SIC:137).
The two treatment groups did not differ regarding age, sex, body mass index (BMI), and American Society of Anesthesiologists (ASA) classification (table 2). None of the 257 patients were lost to follow-up and resources of all patients could be determined.
The numbers of converted procedures, hospital stay, the number of residents performing the procedure, and the number of intra-operative and postoperative complications were not significantly different. Operative time was significantly shorter in the small-incision group (difference 11 minutes, 95% confidence interval (CI) 6 to 17 minutes; p < 0.001) (table 3). The total costs for both treatment groups including all 257 patients are summarized (Table 4).
There is an important difference in direct costs. The difference is caused by differences in costs due to complications and rendering total costs in favor of the laparoscopic procedure.
The difference in operation theatre cost is in favor of the SIC group however. Operation theatre costs are over 23% more expensive in the LC group compared to the SIC group (LC: 1112 euro compared to SIC: 901 euro; difference 211 euro, p < 0.001). Indirect costs are higher in the laparoscopic group.
Data of costs are non-Gaussian distributed, importantly influenced by one extreme outlier. Therefore, although intention-to-treat is violated, the results excluding one outlier in each group are also shown (Table 4). Results in the cost categories admittance and outpatients' clinic do not change. There still is a difference in operation theatre costs in favor of the SIC group (difference 203 euro; 95% CI 147 to 259 euros). In the total costs, there is a difference in favor of the SIC group. All patients were operated using reusable laparoscopic instruments and costs were calculated accordingly.
In order to be able to compare uncomplicated LC and SIC procedures, costs were also calculated excluding all complicated cases. There still are differences present in the operation theatre related costs (difference 199 euro; 95% CI 139 to 259 euro; p < 0.001) and in total direct costs (difference 139 euro; 95% CI 42 to 237 euro; p = 0.006). No significant differences were observed in other direct cost categories, indirect costs, and total costs.
In order to estimate the influence of indirect costs on total costs we performed calculations only including employed patients (Table 5). Indirect costs appear to amount over 60% of total costs in both groups.
We performed a sensitivity analysis assuming the use of disposable instead of reusable laparoscopic instruments. Calculations show increase of operation costs resulting in differences of approximately 960 euro in favor of the SIC group (95% CI 912 to 1024 euro; p < 0.001).
A sensitivity analysis assuming a decrease in work leave by 1 week for the employed patients (n = 101) in this trial results in savings of 82790 euro. In another sensitivity analysis assuming a decrease in hospital stay by 1 night for the employed patients (n = 101) in this trial results in savings of 22980 euro.
When no differences in primary outcomes are found, consequently, several secondary outcome measures like operative time, hospital stay, and time to recovery as well as costs can be chosen as focus for a trial. Most of these secondary outcome measures are incorporated in a total cost assessment. Our cost analyses show that SIC is more expensive compared to LC when all patients are included (intention to treat, Table 4). Excluding one outlier from analyses in each group, total costs per patient are higher in the LC group (p = 0.034). This difference is caused by a difference in operative costs (difference 203 euro; 95% CI 147 to 259 euro; p < 0.001) and a difference in indirect costs (p = 0.315). When all complicated cases are excluded, direct costs (p = 0.006) and operative costs (199 euro, p < 0.001) per patient remain higher in the LC group (using reusable laparoscopic instruments).
The problem in reporting costs are non-Gaussian distributions. Following intention-to-treat principles, complicated cases should be included to obtain an objective impression of absolute costs. Using means results in a biased impression of falsely increased measures as a consequence of skewed data, while using medians would ignore complicated cases since in cholecystectomy about 80% of operations are uneventful procedures (Table 4). In our trial one extreme outlier occurred. Differences in techniques have to be distinguished from random variations. Meta-analyses demonstrate no differences in complications between laparoscopic and small-incision cholecystectomy. We therefore believe that differences in complication costs should be considered random variations. Moreover, our trial was not powered to detect differences in complication costs and these results should be considered a spurious finding and should therefore not be statistically tested at all. Reporting costs excluding one outlier in each group might therefore be more correct as it incorporates complication costs but prohibits distortion of total costs by random extreme outliers.
There are several problems in analyzing and pooling cost results from different studies. First of all, costs are reported in different ways including different cost items. A second problem is that different points of views are taken. These different perspectives make comparison of studies difficult. A third problem is the difference in validity of the cost assessments, defined by the details in which costs are calculated. More detailed analyses are known for more reliable estimates, while less detailed studies cause severe bias.[28, 29] A fourth problem in comparing studies is that there may be considerable differences in local costs. Specific items in cost analyses differ from one country or even setting to another. A fifth and probably most important problem are cultural differences. There are wide variations in convalescence (and return to work) between different cultures depending on a multitude of causes, like social security and cultural habits.[38, 39] As multiple factors cause heterogeneity, pooling results seems inappropriate and one may only draw general conclusions from individual studies.
In literature six trials report costs and lack of methodological quality was present in several trials.[10, 12, 14, 40] In some trials methodology of cost assessment was very limited described.[12, 40] Outpatients' costs [11, 12] and indirect costs.[10–12, 14] are excluded in several studies making overall (societal) comparison of techniques incomplete. Retrospective analyses  or expert settings [11, 14] raise questions on reliability and generalisability. In our trial surgical residents performed 86% of the operations.
The trials by Calvert and Nilsson are high quality trials.[11, 13] Unfortunately, outpatients' clinic costs and indirect costs are not included in the trial by Calvert. Additionally, median hospital stay and estimated operative time (instead of individual data) are used for calculations. They concluded that hospital costs using the laparoscopic technique were 29% higher. The trial by Nilsson is a high quality multi-centre trial. However, standardization of procedures is less biased and more uniform in a single-centre trial compared to a multi-centre trial. Costs are reported in medians (ignoring outliers and complications). This study found lower direct costs and higher indirect costs for the SIC group.
Some conclusions of differences in costs were based on differences in hospital stay  or convalescence.[13, 14] However, in meta-analysis no differences were found in hospital stay and convalescence between both techniques. The differences in indirect costs in our trial should be considered as random variations caused by random differences in age and sex between both groups in the employed patients: calculated friction costs per hour per employee are higher for male and for higher aged employees.
Remarkably, the trials with lack in methodological or cost assessment quality [10, 14, 40] favor the laparoscopic technique, while the trials with high methodological quality or more detailed cost assessments [11, 13] favor the small-incision technique. This linkage between unclear/inadequate methodological quality to significant overestimation of beneficial effects and underreporting of adverse effects is in concordance with other studies.[8, 41, 42]
Different parties have different interests in cost analyses. Though, all perspectives belong to our society. Advantages of a certain therapy in a societal perspective should be given more importance compared to other perspectives not including all cost categories. It provides the most comprehensive assessment and is most relevant for national policy decisions. Implementation at a local level, however, may require to also taking into account a hospital perspective as financial consequences will become visible.
Feasibility of ambulatory cholecystectomy [43, 44] and the wide range in return to work from a few days to 12 weeks raises questions on potential savings. Possibilities for future savings by reduction of hospital stay (direct costs), irrespective of the operating technique for cholecystectomy, were compared to savings by reduction of sick leave (indirect costs). Assuming 21000 cholecystectomies in the Netherlands, reducing hospital stay by one night (50%) in every patient would result in potential savings of 4.8 million euro in the Netherlands annually. Assuming that 50% of the cholecystectomy patients are employed (Table 5), reducing sick leave by one week (25%) in every employed patient would lead to savings of 8.6 million euro on a national basis annually. Based on these hypothetical figures it seems easier to achieve savings by earlier return to work instead of reducing hospital stay. Moreover, as more than 60% of costs of employed patients are caused by sick leave it is more logical to focus on this cost category.
Assuming 21000 cholecystectomies in the Netherlands and an employment ratio of 50%, calculations of sensitivity analyses on hypothetical savings were performed considering change in policy from disposable to reusable laparoscopic instruments, change from LC to SIC, or reducing sick leave by one week. As a result savings of approximately 16 million, 4.2 million and 8.6 million euro respectively are possible on a national basis annually. However, conclusions have to be careful since calculations are hypothetical.
In this single-centre trial with representative results and emphasis on methodological quality LC appears more costly: the procedural costs surpass those of SIC (and use of disposable instruments would only further increase this difference). Thus SIC is the preferred operative technique over LC both from a hospital and societal cost perspective.
Sick leave associated with convalescence after surgery results in considerable costs to society especially in the employed patient.
Langenbuch C: Ein Fall von Exstirpation der Gallenblase wegen chonischer Cholelithiasis: Heilung. Berliner Klin Wochenschr. 1882, 19: 725-727.
Dubois F, Berthelot B: [Cholecystectomy through minimal incision (author's transl)] Cholecystectomie par mini-laparotomie. Nouv Presse Med. 1982, 11: 1139-1141.
Goco IR, Chambers LG: "Mini-cholecystectomy" and operative cholangiography. A means of cost containment. Am Surg. 1983, 49: 143-145.
NIH Consensus conference: Gallstones and laparoscopic cholecystectomy. JAMA. 1993, 269: 1018-1024. 10.1001/jama.269.8.1018.
Escarce JJ: Externalities in hospitals and physician adoption of a new surgical technology: an exploratory analysis. J Health Econ. 1996, 15: 715-734. 10.1016/S0167-6296(96)00501-2.
Keus F, de Jong JAF, Gooszen HG, van Laarhoven CJHM: Small-incision versus open cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev. 2006, 4: CD004788-
Keus F, de Jong JAF, Gooszen HG, van Laarhoven CJHM: Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev. 2006, 4: CD006231-
Keus F, de Jong JAF, Gooszen HG, van Laarhoven CJHM: Laparoscopic versus small-incision cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev. 2006, 4: CD006229-
Keus F, Werner J, Gooszen HG, Oostvogel HJM, Laarhoven van CJHM: Randomized clinical trial on small-incision and laparoscopic cholecystectomy in patients with symptomatic cholecystolithiasis: primary and clinical outcome. Arch Surg. 2008, 143: 371-377. 10.1001/archsurg.143.4.371.
Barkun JS, Caro JJ, Barkun AN, Trindade E: Cost-effectiveness of laparoscopic and mini-cholecystectomy in a prospective randomized trial. Surg Endosc. 1995, 9: 1221-1224.
Calvert NW, Troy GP, Johnson AG: Laparoscopic cholecystectomy: a good buy? A cost comparison with small-incision (mini) cholecystectomy. Eur J Surg. 2000, 166: 782-786. 10.1080/110241500447416.
McMahon AJ, Russell IT, Baxter JN, Ross S, Anderson JR, Morran CG: Laparoscopic versus minilaparotomy cholecystectomy: a randomised trial. Lancet. 1994, 343: 135-138. 10.1016/S0140-6736(94)90932-6.
Nilsson E, Ros A, Rahmqvist M, Backman K, Carlsson P: Cholecystectomy: costs and health-related quality of life: a comparison of two techniques. Int J Qual Health Care. 2004, 16: 473-482. 10.1093/intqhc/mzh077.
Secco GB, Cataletti M, Bonfante P, Baldi E, Davini MD, Biasotti B: [Laparoscopic versus mini-cholecystectomy: analysis of hospital costs and social costs in a prospective randomized study] Video-colecistectomia versus mini-colecistectomia: analisi dei costi ospedalieri e dei costi sociali in uno studio prospettico randomizzato. Chir Ital. 2002, 54: 685-692.
Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A: Cost-effectiveness analysis of laparoscopic versus minilaparotomy cholecystectomy for gallstone disease. A randomized trial. Int J Technol Assess Health Care. 2001, 17: 497-502.
Keus F, Ahmed Ali U, Noordergraaf GJ, Roukema JA, Gooszen HG, van Laarhoven CJHM: Anaesthesiological considerations in small-incision and laaroscopic cholecystectomy in symptomatic cholecystolithiasis: implications for pulmonary function. A randomized clinical trial. Acta Anaesthesiol Scand. 2007, 51: 1068-1078. 10.1111/j.1399-6576.2007.01386.x.
Keus F, de Vries J, Gooszen HG, van Laarhoven CJHM: Laparoscopic versus small-incision cholecystectomy: health status in a blind randomized trial. Surg Endosc. 2008, 22: 1649-1659. 10.1007/s00464-007-9675-0.
Pocock SJ: Clinical Trials: A practical approach. 1987, John Wiley & Sons
Majeed AW, Troy G, Nicholl JP, Smythe A, Reed MW, Stoddard CJ: Randomised, prospective, single-blind comparison of laparoscopic versus small-incision cholecystectomy. Lancet. 1996, 347: 989-994. 10.1016/S0140-6736(96)90143-9.
Rocko JM, Di Gioia JM: Calot's triangle revisited. Surg Gynecol Obstet. 1981, 153: 410-414.
Coelho JC, de Araujo RP, Marchesini JB, Coelho IC, de Araujo LR: Pulmonary function after cholecystectomy performed through Kocher's incision, a mini-incision, and laparoscopy. World J Surg. 1993, 17: 544-546. 10.1007/BF01655120.
Grande M, Tucci GF, Adorisio O, Barini A, Rulli F, Neri A: Systemic acute-phase response after laparoscopic and open cholecystectomy. Surg Endosc. 2002, 16: 313-316. 10.1007/s00464-001-9042-5.
McGinn FP, Miles AJ, Uglow M, Ozmen M, Terzi C, Humby M: Randomized trial of laparoscopic cholecystectomy and mini-cholecystectomy. Br J Surg. 1995, 82: 1374-1377. 10.1002/bjs.1800821027.
Ros A, Gustafsson L, Krook H, Nordgren CE, Thorell A, Wallin G: Laparoscopic cholecystectomy versus mini-laparotomy cholecystectomy: a prospective, randomized, single-blind study. Ann Surg. 2001, 234: 741-749. 10.1097/00000658-200112000-00005.
Tate JJ, Lau WY, Leung KL, Li AK: Laparoscopic versus mini-incision cholecystectomy. Lancet. 1993, 341: 1214-1215. 10.1016/0140-6736(93)91042-K.
Walker CB, Bruce DM, Heys SD, Gough DB, Binnie NR, Eremin O: Minimal modulation of lymphocyte and natural killer cell subsets following minimal access surgery. Am J Surg. 1999, 177: 48-54. 10.1016/S0002-9610(98)00290-6.
Kirkwood BR, Sterne JAC: Essential medical statistics. 2003, Oxford, UK, Blackwell science Ltd, 2
Drummond MF, Jefferson TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996, 313: 275-283.
Graves N, Walker D, Raine R, Hutchings A, Roberts JA: Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ. 2002, 11: 735-739. 10.1002/hec.683.
Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. 1996, New York: Oxford University Press, 1
Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR: Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics. 1997, 11: 159-168. 10.2165/00019053-199711020-00005.
Oostenbrink JB, Koopmanschap MA, Rutten FF: Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics. 2002, 20: 443-454. 10.2165/00019053-200220070-00002.
Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992, 34: 1005-1010. 10.1016/0277-9536(92)90131-9.
Koopmanschap MA, Rutten FF: A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996, 10: 460-466. 10.2165/00019053-199610050-00003.
Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG: Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ. 1997, 6: 505-510. 10.1002/(SICI)1099-1050(199709)6:5<505::AID-HEC294>3.0.CO;2-I.
Dutch Healthcare Authority (Nederlandse Zorgautoriteit, NZa). 2006, [http://www.nza.nl]
Egger M, Juni P, Bartlett C: Value of flow diagrams in reports of randomized controlled trials. JAMA. 2001, 285: 1996-1999. 10.1001/jama.285.15.1996.
Vitale GC, Collet D, Larson GM, Cheadle WG, Miller FB, Perissat J: Interruption of professional and home activity after laparoscopic cholecystectomy among French and American patients. Am J Surg. 1991, 161: 396-398. 10.1016/0002-9610(91)90606-E.
Majeed AW, Brown S, Williams N, Hannay DR, Johnson AG: Variations in medical attitudes to postoperative recovery period. BMJ. 1995, 311: 296-
Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A: Cost-effectiveness analysis of laparoscopic versus minilaparotomy cholecystectomy for gallstone disease. A randomized trial. Int J Technol Assess Health Care. 2001, 17: 497-502.
Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995, 273: 408-412. 10.1001/jama.273.5.408.
Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG: Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008, 336: 601-605. 10.1136/bmj.39465.451748.AD.
Ledet WP: Ambulatory cholecystectomy without disability. Arch Surg. 1990, 125: 1434-1435.
Seale AK, Ledet WP: Minicholecystectomy: a safe, cost-effective day surgery procedure. Arch Surg. 1999, 134: 308-310. 10.1001/archsurg.134.3.308.
We thank the financial department of the St. Elisabeth hospital, Tilburg, The Netherlands for their cooperation.
Funding: Foundation 'Gasthuisraad', a foundation for scientific research Midden-Brabant, The Netherlands.
Other outcome measures from this study have been previously published in Arch Surg. 2008 Apr;143(4):371-7; Acta Anaesthesiol Scand 2008 Mar;52(3):363-73; and Surg Endosc. 2008 Jul;22(7):1649-59.
The authors declare that they have no competing interests.
FK and CJHML had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. FK, CJHML, EB and HGG participated in study concept and design. FK, TJ and CJHML participated in the acquisition of data. FK, HGG, CJHML participated in the analysis and interpretation of data. KF and TJ drafted the manuscript. HGG, EB and CJHML were responsible for critical revision of the manuscript for important intellectual content. FK, EB and CJHML participated in statistical analysis. FK and CJHML obtained funding. FK, TJ and CJHML were responsible for administrative, technical, and material support. HGG and CJHML supervised the study.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Keus, F., de Jonge, T., Gooszen, H.G. et al. Cost-minimization analysis in a blind randomized trial on small-incision versus laparoscopic cholecystectomy from a societal perspective: sick leave outweighs efforts in hospital savings. Trials 10, 80 (2009). https://doi.org/10.1186/1745-6215-10-80
- Laparoscopic Cholecystectomy
- Indirect Cost
- Sick Leave
- Societal Perspective
- Cost Price